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ABSTRACT
Background: Glycopeptide antibiotics are considered by many investigators
to be the last resort in the treatment of gram-positive bacterial infections.
Objective: The aim of this review was to assess the place of glycopeptides
in the treatment of common gram-positive bacteria in accordance with the cur-
rent epidemiologic data in Turkey.
Methods: A search of both the English- and Turkish-language literature
indexed on MEDLINE, Ulakbim (Turkey), and Pleksus (Turkey) was performed
using the terms: vancomycin, teicoplanin, and glycopeptides, or their Turkish-
language counterparts. The complete texts of the articles found in these data-
bases were obtained from the electronic library of Gulhane Medical Academy,
Ankara, Turkey. Articles from regional journals, without the support of an elec-
tronic format, were obtained by direct communication. Articles of interest were
those based on studies occurring in Turkish populations, with special consid-
eration given to publications in press after 2002.
Results: Staphylococci were the most frequent gram-positive pathogens
encountered in Turkish hospitals. Studies have found that ~74% of strains were
Staphylococcus aureus and the remaining strains were coagulase-negative
staphylococci (CoNS). Overall methicillin resistance in staphylococci was
reported as ~60%. In Turkey, S aureus was one of the most common infectious
agents found inside hospitals and is deemed a growing threat in the community.
While the rate of methicillin resistance in community-acquired isolates is ~4%,
the data from hospitals suggest that reduced resistance comprises most of the
isolates. In the studies reviewed, older quinolones like ciprofloxacin and
ofloxacin seem to be ineffective in nearly half of the S aureus isolates. Alternatives
like rifampicin, gentamicin, tetracycline, trimethoprim/sulfamethoxazole
(TMP/SMX), clindamycin, and erythromycin have had substantial resistance
profiles in >50% of the strains. In recent Turkish studies, in vitro profiles of li-
nezolid, quinupristin/dalfopristin (QD), and daptomycin have had positive
results. As in the S aureus isolates, resistance trends have been observed in
the CoNS group of pathogens. The possible use of β-lactams seems restricted,
V O L U M E 68,  N U M B E R 1 ,  J A N U A R Y / F E B R U A R Y 2007
C U R R E N T T H E R A P E U T I C R E S E A R C H
Copyright © 2007 Excerpta Medica, Inc. 49
Accepted for publication December 19, 2006. doi:10.1016/j.curtheres.2007.03.001
Reproduction in whole or part is not permitted. 0011-393X/$32.00
49_CTRV68N1_erdem  3/13/07  2:49 PM  Page 49
CURRENT THERAPEUTIC RESEARCH
50
and alternative approaches have become necessary. Quinolones, gentamicin,
tetracycline, TMP/SMX, clindamycin, and erythromycin have resistance profiles
of >50%. Although glycopeptide resistance was not detected, the frequency of
heterogenous vancomycin-intermediate S aureus, a precursor to future resis-
tance, was 13% in 1 study. Current studies in Turkey have found that Enterococcus
faecalis comprises three quarters of enterococci while the rest are comprised
of Enterococcus faecium. Initial studies performed with linezolid, QD, and 
daptomycin suggest that these drugs might be effective alternatives for future
enterococcal infections that may have high glycopeptide resistance. Ap-
proximately 8% of the Streptococcus pneumoniae strains had high-level resis-
tance in Turkey. However, 10 million units of crystallized penicillin or 3 g of oral
amoxicillin maintains the optimum treatment of pneumococcal infections out-
side the central nervous system (CNS). Resistance profiles in third-generation
cephalosporins in Turkey range between 2% and 2.5%.
Conclusions: In Turkey, a review of the existing literature found that the
current use of glycopeptides in pneumococcal infections is restricted to CNS
infections facing therapeutic failure in due course. However, the belief that
these drugs are the last resort, either in staphylococcal or enterococcal
infections, is no longer valid. If a patient has a critical status due to probable
gram-positive microorganisms, clinicians should consider the empiric use of
glycopeptides. However, new molecules such as linezolid, QD, and daptomycin,
offered for use in the treatment of gram-positive bacterial diseases, should
be reserved for the future, when glycopeptides eventually become obsolete.
(Curr Ther Res Clin Exp. 2007;68:49–66) Copyright © 2007 Excerpta Medica, Inc.
Key words: glycopeptides, Turkey.
INTRODUCTION
Vancomycin is an antibiotic from the glycopeptide class. Initial use of this drug
was limited due to its substantial toxicity.1 However, its use was reconsidered with
the emergence of methicillin-resistant Staphylococcus aureus (MRSA).2 Vancomycin
and teicoplanin are known as first-generation glycopeptides. Oritavancin is the
first clinical candidate in what have been called second-generation glycopeptides.3
These agents have also been labeled as lipoglycopeptides due to their hydropho-
bic components. Chloroeremomycin, dalbavancin, telavancin, and mannopepti-
mycin analog AC98-6446 are all of the new molecules.1
Glycopeptide antibiotics are considered by many investigators the last
resort in gram-positive bacterial infections. Data from in vitro, experimental,
and clinical studies have suggested that vancomycin is a less effective agent than
β-lactams against susceptible bacteria.4 One common explanation for this
observation appears to be the slow bactericidal effects of vancomycin.5 Therefore, 
isolates that are methicillin- or penicillin-susceptible should be treated with 
β-lactams rather than vancomycin.4 However, steadily increasing resistance
profiles might force clinicians to reconsider glycopeptide use in the future.
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Turkey is a large country in southeastern Europe with a population of ~75 mil-
lion. In that country, gram-positive pathogens, in which coagulase-negative
staphylococci (CoNS), enterococci, and S aureus are the most common species,
have been associated with ~50% of the infections in hospitals.1,6–10 These
pathogens are likely to have accelerated resistance patterns throughout the
country.9–13 The aim of this review was to assess the place of glycopeptides in
the treatment of common gram-positive bacteria in accordance with the current
epidemiologic data in Turkey.
Staphylococci 
Multidrug resistance is the primary problem in the management of staphylo-
coccal infections particularly if the infecting strain is methicillin resistant. In
Turkey, almost all of the isolates with methicillin nonsusceptibility have multi-
drug resistance.14–16 Consequently, these microorganisms are the causative
agents of difficult-to-treat infections with limited antibiotic choices owing to the
current epidemiologic direction.
Worldwide outbreaks of MRSA infections were reported as early as the 1960s,
shortly after the introduction of methicillin in 1959.17 The evidence suggests
that a single clone of MRSA accounted for most of the isolates recovered during
that period. Today, MRSA has increased prevalence rates worldwide as both a
nosocomial and, more recently, a community-acquired pathogen.2,18 By 2002, 
5 major MRSA clones had emerged worldwide.19
Methicillin resistance in S aureus is defined as an oxacillin MIC ≥4 µg/mL.20
Isolates resistant to oxacillin or methicillin are also resistant to all β-lactam
agents including cephalosporins. The presence of the mec gene is an absolute
requirement for S aureus to express methicillin resistance. The mec gene is
absent from susceptible strains and present in all resistant strains.21
MecA encodes penicillin-binding protein (PBP) 2a. PBP2a is a novel, inducible
76-kDa protein that establishes resistance to β-lactams.22 The net effect of this
resistance pattern in clinical practice is the need to use glycopeptides.
Heterogenous vancomycin-intermediate S aureus (hetero-VISA) are suscepti-
ble to vancomycin according to the Clinical and Laboratory Standards Institute
(formerly NCCLS) MIC criteria (MIC ≤4 mg/L), but contain subpopulations at
a frequency of 10–6 CFUs or higher with MICs in vancomycin of >4 mg/L.23
Detection of vancomycin-intermediate S aureus (VISA) is possible with standard
laboratory techniques, although detection of hetero-VISA strains is problematic.
Hetero-VISA isolates are the precursors of VISA and, consequently, trailing these
strains might be clues for the future VISA or perhaps vancomycin-resistant 
S aureus (VRSA) infections.9,23
Intermediate glycopeptide resistance arises from chromosomal mutations
that affect the structure of the cell wall peptidoglycan.24 In susceptible strains,
glycopeptides inhibit cell wall assembly by binding to the D-Ala-D-Ala terminus of
cell wall precursors, thus blocking transpeptidation.25 VISAs harbor a thickened
cell wall that contains an increased number of free, uncrosslinked D-Ala-D-Ala ter-
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minals. This increased amount is thought to act as a lure and traps glycopeptide
molecules before they reach their target.26 Although VISAs might cause glycopep-
tide treatment failure, their low level of resistance, and sometimes heterogeneous
phenotype, make them difficult to detect in the laboratory.27 Therefore, their epi-
demiologic meaning is difficult to appraise. Special techniques such as screening
on vancomycin-containing plates (4 mg/L) and population analysis profiles are
needed to detect these phenotypes.28
Full vancomycin resistance (MIC >32 mg/L) has been known to exist for more
than a decade in Enterococcus spp.29 In these organisms, glycopeptide resistance
results from the acquisition of either Tn1546 or Tn1547, 2 transposons encoding
for a series of genes modifying the D-Ala-D-Ala terminus of the bacterial peptido-
glycan precursor, the target of glycopeptide compounds to D-Ala-D-lactate. The
modified D-Ala-D-lactate–containing precursor has a low affinity for the glycopep-
tides and thus confers resistance. Tn1546, encoding the so-called VanA resis-
tance phenotype, may be transferred to S aureus experimentally.30 Therefore, it
is not surprising that total VRSA expressing the VanA phenotype have emerged
among human clinical isolates.31 Although these organisms are still rare, they
must be taken very seriously.
Data from in vitro, experimental, and clinical studies suggest that van-
comycin is a less effective agent than the β-lactams against susceptible strains
of S aureus.4,32,33 However, community-associated MRSA infections are most
often associated with soft tissue infections and generally patients receive initial
treatment with antibiotics to which their isolate is not susceptible.34 Oc-
casionally, patients with MRSA infection are either allergic or unable to tolerate
treatment with glycopeptides. A variety of other agents has been used in such
patients, but none is ideal. When vancomycin administration is not feasible,
patients with MRSA infections have been treated with fluoroquinolones,
trimethoprim/sulfamethoxazole (TMP/SMX), clindamycin, and minocycline. Al-
though all have been effective in treating patients who require bactericide
treatment, each has less intrinsic activity against staphylococci than vanco-
mycin.35–37 This makes clinician awareness of antimicrobial susceptibility 
patterns an urgent matter of importance with regard to this group of patho-
gens. In addition to older drugs, a number of novel antibiotics with anti-
staphylococcic activity have been approved or are under investigation. These
include, linezolid, quinupristin-dalfopristin (QD), daptomycin, evernimicin, and
lysostaphin.1,25,26
CoNS are common colonizers of human skin and the most frequent con-
stituent of the normal flora at this site.38 Once considered relatively avirulent
and possibly a contaminant when isolated from a clinical specimen, these
organisms have become increasingly recognized as agents of clinically signifi-
cant nosocomial infections. The prevalence of methicillin resistance among
CoNS rose from 20% to 60% between 1980 and 1989 in the United States.39 It is
believed that the mec gene was acquired from these closely related staphylo-
coccal species via a limited number of genetic events. The mec gene is essen-
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tially the same in all staphylococcal species. Several studies40 point to CoNS as
the origin of methicillin resistance in S aureus.
Patients at risk include immunocompromised hosts and those with pros-
thetic devices, intravascular catheters, and other foreign bodies in place.41
These infections are inherently difficult to treat given the frequent presence of
foreign material and the often multiple drug-resistant nature of the organisms.
Prosthetic devices are presumably inoculated with small numbers of CoNS at
the time of implantation. The organisms might originate from the flora of the
patient or surgical staff, or from the environment. Intravascular catheters are
colonized by skin flora, which can either migrate down the external portion of
the catheter tunnel or colonize the hub with catheter manipulations, thereby
gaining access to the internal surface of the catheter.42 Infected and easily
removable prosthetic devices like peripheral catheters do not necessitate
antibiotics after the elimination of the device, although treatment is generally
attempted with hard-to-replace implants.43,44
Enterococci
Enterococci result in bacteremia, urinary tract infections, endocarditis, surgical
site infections, and intra-abdominal infections.45–49 Enterococci are the ideal
pathogens because they survive easily under the extreme levels of pH and temper-
ature, and with the presence of salt and bile in their environment.50 These
pathogens have been suggested to be the primary causes of nosocomial out-
breaks.14 They have evolved a number of efficient methods (eg, plasmids, trans-
posons, chromosomal exchange, mutations) for transferring resistance genes
among themselves, and between themselves and other organisms, greatly facilitat-
ing their acquisition of new resistance determinants.51 They also have intrinsic
resistance to aminoglycosides (low level), β-lactams (relatively high MICs), and lin-
cosamides (low level). A number of phenotypes of vancomycin resistance have
been discovered.52 Strains exhibiting the VanA phenotype show high-level resis-
tance to vancomycin and teicoplanin, and VanB strains exhibit moderate- to high-
level resistance to vancomycin but remain susceptible to teicoplanin. The
genes for both of these resistance phenotypes have been cloned and sequenced
and have been suggested to be transferable.53 Vancomycin was and is still used 
frequently where glycopeptide-susceptible ampicillin-resistant enterococci
may be encountered.54 However, resistance was inevitable and the first isolates
of vancomycin-resistant enterococci (VRE) were reported from England and
France.55,56
Vancomycin resistance of the VanA phenotype is the result of the production
of a ligase with altered specificity that results in the synthesis of cell wall pre-
cursors ending in the depsipeptide D-alanyl-lactate rather than the dipeptide 
D-alanyl-D-alanine, which is the target for vancomycin. Vancomycin resistance is
the result of the inability of vancomycin to bind to the altered depsipeptide, which
can nonetheless be crosslinked by enterococcal transpeptidase to form a normal
cell wall and thus does not result in a selective disadvantage to the enterococci.1,25
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Low levels of vancomycin resistance without teicoplanin resistance have
also been found in Enterococcus gallinarum (VanC) and Enterococcus cas-
seliflavus.57,58 A fourth vancomycin-resistant genotype VanD, has been
described in a strain of Enterococcus faecium that exhibited moderate levels
of resistance to vancomycin and teicoplanin.59 Enterococcus faecalis and 
E faecium are the most frequently encountered enterococcal species in medi-
cal practice.52 E faecalis is the more frequent while E faecium is the more re-
sistant pathogen.8
The combination of aminoglycosides and β-lactams produces synergism in
enterococcal disease. The limitation of aminoglycoside penetration through the
bacterial cell wall results in intrinsic low-level resistance. If a combination is
established with a bacterial cell wall inhibitor, synergy is obtained due to the
facilitated influx of the aminoglycoside. Given the fact that these organisms are
naturally resistant to cephalosporins, penicillinase-resistant penicillins, and low-
dose aminoglycosides used in the management of other gram-positive bacterial
infections, therapeutic management poses serious problems.54 Enterococci are
also 100-fold less susceptible to β-lactams when compared with streptococci50,60
and might easily develop resistance to β-lactams, aminoglycosides, or even to
glycopeptides.54 Unfortunately, the development of high-level resistance (HLR)
to aminoglycosides eliminates the synergistic mechanism between β-lactams
and aminoglycosides.50 Consequently, observing HLR is important and is one
of the key elements to enlightening the utilization of glycopeptides in entero-
coccal disease.
Streptococcus pneumoniae
Pneumococci (S pneumoniae) cause various infections including purulent
meningitis, acute otitis media, acute sinusitis, and pneumonia.12 Consequently,
pneumococcus is a commonly encountered pathogen in health care set-
tings.61,62 From the start of the antibiotic era, that began with the invention of
penicillin to the mid-1970s, pneumococci remained uniformly susceptible to all
classes of antibiotics that had been active against the organisms, with the pos-
sible exception of tetracycline. Thus, the medical profession had a rude awak-
ening in 1977 and 1978 when outbreaks of infection due to antibiotic-resistant
pneumococci occurred in South Africa.63 Today, pneumococci have elevated
resistance profiles throughout the world.12,64 Penicillin MIC thresholds in this
group of pathogens are susceptible for values <0.06 µg/mL, intermediate resis-
tance from 0.06 to 1.0 µg/mL, and full resistance for those >2.0 µg/mL.20
However, in daily medical practice, the understanding shared by most clini-
cians is to take the MIC values >4 µg/mL into account for full resistance, exclud-
ing central nervous system (CNS) isolates.64,65
In Turkey, according to Duygu Cevik, medical manager of teicoplanin (The
sanofi-aventis Group, September 2006), vancomycin and teicoplanin have been
the sole glycopeptides on the market since 1988 and 1996, respectively. The aim
of this article was to assess the place of glycopeptides in the treatment of infec-
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tions with the aforementioned microorganisms in accordance with the current
epidemiologic data in Turkey.
MATERIALS AND METHODS
A search of both the English- and Turkish-language literature indexed on MED-
LINE, Ulakbim (Turkey), and Pleksus (Turkey) was performed using the terms
vancomycin, teicoplanin, and glycopeptides, or their Turkish-language counter-
parts. The complete texts of the articles found in these databases were
obtained from the electronic library of Gulhane Medical Academy, Ankara,
Turkey. Articles from regional journals, without the support of an electronic for-
mat, were obtained by direct communication. Articles of particular interest
were those based on studies occurring in Turkish populations, with special con-
sideration given to publications in press after 2002. No articles were excluded
from this review.
RESULTS
Staphylococci
Staphylococci were the most frequent gram-positive pathogens encountered
in Turkish hospitals.6 In a study45 that included 28 institutions in Turkey, ~74% of
the strains were S aureus and the remaining 26% were CoNS. The overall methi-
cillin resistance in staphylococci was ~60% in that report. The current studies
available regarding staphylococcus resistance in Turkey are shown in Table I.
In Turkey, S aureus was one of the most common infectious agents found
inside hospitals and is deemed a growing threat in the community.66,67
Penicillin, the historically safe-to-use antibiotic, is no longer effective in infec-
tions associated with this microbe.16,68,69 Local reports of methicillin resistance
have varied. While the rate of community-acquired isolates was ~4% in 1 re-
port,15 the data from hospitals suggest that reduced resistance comprises most
of the isolates.6,10,15,16,68,70–74 In addition, methicillin nonsusceptible isolates
presenting much greater resistance to alternative drugs have been confirmed in
the studies we analyzed.14,45,74–76
In current Turkish studies, hetero-VISA has been detected in 1% to 20% of
the isolates,9,77,78 and no VRSA isolates have been observed in epidemiologic
reports.16,70,71,79 We could find no record on VISA in the databases, although
1 isolate was recovered from the blood culture of a patient with endocarditis
hospitalized in our institution (Gulhane Medical Academy, Ankara, Turkey).
In the studies reviewed, older quinolones like ciprofloxacin and ofloxacin
seem to be ineffective in nearly half of the S aureus isolates.16,45,68,70,80–82 Although
the same was true for levofloxacin and differences have not been observed
between the older- and newer-generation quinolones, cumulative data are lack-
ing for a drastic concurrence.79,83 Other alternatives like rifampicin, gentamicin,
tetracycline, TMP/SMX, clindamycin, and erythromycin have had substantial
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Table I. Antibiotic resistance in studies of staphylococci in Turkey.
Antibiotic S aureus, % Reference(s) CoNS, % Reference(s)
Overall MDR 12–78 15, 16 96 16
MRSA 100 14 NA NA
MRCoNS NA NA 100 14
Antibiotics, bacterial resistance rate, %
Chloramphenicol 19–28 68, 70 18 87
Ciprofloxacin 9–71 16, 68, 82, 83 30–51 16, 87
MRSA 86 74 NA NA
Clindamycin 40–83 16, 70, 78, 79 79–92 16, 79
Daptomycin 0 75 NA NA
Erythromycin 41–87 16, 68, 75 96 16
MRSA 59 74 NA NA
Fusidic Acid 4–13 7, 75, 76, 85 13–24 7, 85
MRSA 3–20 45, 75, 76 NA NA
MRCoNS NA NA 13 45
Gentamicin 33–51 16, 70, 79, 80, 82 17–58 16, 79
MRSA 76 74 NA NA
Hetero-VISA 0–18 9, 77, 78 13 78
Levofloxacin 22–67 79, 82, 83 50 79
Linezolid 0 86 0 86
MRSA 0 86 NA NA
MRCoNS NA NA 0 86
Methicillin 17–100 6, 10, 15, 16, 68, 14–81 6, 16, 72, 87
70, 71, 72, 73
Moxifloxacin 17 82 NA NA
Ofloxacin 24–63 45, 70, 80, 82, 83 33–67 79, 87
Penicillin 82–100 16, 68, 69 47–100 79, 87
QD 0–1 14, 81, 86 NA NA
Rifampicin 31–53 70, 80, 84 36 87
MRSA 73 74 NA NA
TMP/SMX 10–83 16, 68, 70, 71, 52–75 16, 45, 79
79, 80
Tetracycline 44–67 70, 79, 80 83 79
Vancomycin 0 16, 70, 71, 79 0 79
S aureus = Staphylococcus aureus; CoNS = coagulase-negative staphylococci; MDR = multidrug resistance;
MRSA = methicillin-resistant S aureus; MRCoNS = methicillin-resistant CoNS; NA = not applicable;
hetero-VISA = heterogenous vancomycin-intermediate S aureus; QD = quinupristin/dalfopristin;
TMP/SMX = trimethoprim/sulfamethoxazole.
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resistance profiles in >50% of the strains.16,68,70,71,74,75,79,80,82,84 But chloram-
phenicol had better results, implicating <30% nonsusceptibility in 2 stud-
ies.68,70 The resistance profile of fusidic acid, an oral agent in the Turkish mar-
ket, is also satisfactory.7,45,75,76,85 In several Turkish studies,14,45,75,81,86 in vitro
profiles of linezolid, QD, and daptomycin have shown positive results.
As in the S aureus isolates, resistance trends have been observed in the
CoNS group of pathogens in recent Turkish studies.6,16,72,79,87 The possible
use of β-lactams seems restricted and alternative approaches have become
necessary.
In Turkey, quinolones, gentamicin, tetracycline, TMP/SMX, clindamycin, and
erythromycin have resistance profiles of >50%.16,45,79,81,87 Fusidic acid is a little
more promising with resistance profiles of <30%.7,85 Similar to S aureus, linezo-
lid is very effective in both methicillin-resistant and methicillin-susceptible
isolates.14,45,86 Although glycopeptide resistance was not detected, the fre-
quency of hetero-VISA, a precursor to VISA resistance, was 13% in 1 study.78,79
Enterococci
The first Turkish VRE was isolated in 1996 in the Mediterranean city of
Antalya.14 The second isolate was reported in 2000 from a military hospital
located in Ankara.88 The current studies available regarding enterococcal
resistance in Turkey are presented in Table II. Several studies have stated
that E faecalis comprises three quarters of enterococci while the rest are com-
prised of E faecium.8,89–91 β-Lactamase production has not been detected.8,11,91,92
Although penicillin and ampicillin both seem to be efficient drugs in the man-
agement of infections associated with E faecalis with <10% nonsusceptibility,
the same cannot be said for those associated with E faecium in which three
fourths of the isolates were resistant to these drugs.8,89,90,93
HLR to gentamicin is ~10% to 30%, while the range for streptomycin is
between 20% and 50% for E faecalis, and these impediments are detected in
>50% of E faecium isolates. Based on the evidence, enterococcal strains in
Turkey have been associated with greater resistance to streptomycin than to
gentamicin.8,90,91,93,94
In The Netherlands, VRE was found to increase mortality by 60% to 70%
compared with infections associated with susceptible isolates.95 Most of
the current epidemiologic analyses have not reported VRE throughout the
country,8,54,90,96,97 albeit just 1 local study reported a 19% ratio.7 These satisfac-
tory results seem to be masked with the presence of 79% to 100% vancomycin
tolerance, which was defined as the ratio of minimum bactericidal concentra-
tion to MIC over 32.8,97 Furthermore, 1 study reported intermediate resistance
as 1.6%.14 Intermediate resistance was identified by disk diffusion testing in the
laboratory and, when detected, an additional MIC test was indicated to identify
full resistance.20 Outbreaks of VRE have been observed: 18 infections in a chil-
dren’s hospital in Ankara and 2 outbreaks comprising 20 and 6 cases in the Ege
University hospital.14,73
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Levofloxacin seems to be an efficient drug in E faecalis infections in Turkey
and appears to have similar resistance profiles with ciprofloxacin.89,90,98
Although limited, there are VRE case presentations in which the infecting
strains are levofloxacin susceptible in Turkey.99 The old class of antibiotics (eg,
erythromycin, chloramphenicol, and rifampicin) appears to have limited effi-
cacy on enterococci.89,93 The initial studies performed with linezolid, QD, and
daptomycin suggest that these drugs might be effective alternatives for future
infections that may have high glycopeptide resistance.14,75,86,92,100
Table II. Antibiotic resistance profiles in studies of enterococci in Turkey. 
Antibiotic E faecalis E faecium Total* Reference(s)
Overall frequency 
of resistance, % 65–78 9–30 8, 89, 90, 91
Antibiotics, bacterial resistance rate, %
Ampicillin 10–11 77–82 NA 8, 89, 90, 93
Chloramphenicol 27–30 35–45 NA 89, 93
Ciprofloxacin 15–57 59–90 16 89, 90, 93, 98
Daptomycin NA NA 0 75
Erythromycin 34–64 77–90 NA 89, 93
HLGR 11–28 41–88 26–35 8, 90, 91, 93, 94
HLSR 22–46 35–67 22–48 8, 91, 93, 94
Levofloxacin 8–53 47–73 NA 89, 93
Linezolid NA NA 0 92, 100
VRE NA NA 0–10 14, 86, 100
Penicillin 4–11 74–82 27 8, 90, 93
QD
VRE NA NA 7–10 14, 86
Rifampicin 58–68 65–90 NA 89, 93
Tetracycline 67–71 27–71 NA 89, 93
Vancomycin
VRE NA NA 0 8, 54, 90, 96, 97
VIRE NA NA 1.6 60
VTE NA NA 79–100 8, 97
E faecalis = Enterococcus faecalis; E faecium = Enterococcus faecium; NA = not applicable; HLGR = high-
level gentamicin resistance; HLSR = high-level streptomycin resistance; VRE = vancomycin-resistant
enterococci; QD = quinupristin/dalfopristin; VIRE = vancomycin-intermediate resistant enterococci; VTE =
vancomycin-tolerant enterococci.
*Total column represents enterococci on the whole.
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Streptococcus pneumoniae
By the year 2005, the penicillin resistance in S pneumoniae was ~40% in clini-
cal isolates. On the whole, ~20% of the resistant strains had HLR in Turkey.12
Our review of the literature revealed that MIC90 of the pneumococci was 
1 µg/mL and all of the isolates had MIC levels <4 µg/mL.12,62 However, 10 million
units of crystallized penicillin or 3 g of oral amoxicillin maintains the optimum
treatment of pneumococcal infections outside the CNS.62
The streptococcal resistance profiles in third-generation cephalosporins in
Turkey range between 2% and 2.5%.12,61 One large-scale study reported the
prevalence of ceftriaxone resistance among penicillin-resistant isolates (n = 76)
as 5.3%.101
DISCUSSION
Based on the finding that most of the S aureus have been found to be methicillin
resistant, β-lactam antibiotics are likely of little use in Turkish hospitals. As
methicillin nonsusceptible isolates have presented much greater resistance to
alternative drugs,14,45,74–76 movement between medical institutions and the
community might result in elevated resistance patterns outside of hospitals.
And, although they are not being reported, VISA isolates have been known to
occur. Because resistance is increasing throughout Turkey, it is important for
Turkish physicians to culture pathogens with susceptibility testing prior to ini-
tiation of treatment.
Positive resistance profiles have been determined for new drugs such as linezo-
lid, QD, and daptomycin. However, under the current circumstances of increas-
ing resistance, it is our opinion that these drugs must be reserved for future
resistant pathogens and should be used cautiously. One current indication is
that if the pharmacodynamic properties of these drugs necessitate their use, as
in nosocomial meningitis due to multidrug-resistant gram-positives, they might
be preferred because the efficacy of glycopeptides is suboptimal in these types
of infections.102
In our opinion, glycopeptides will be experiencing incremental loss of effi-
cacy with CoNS soon and obtaining culture is the gold standard approach in
medical practice with nonsusceptibility profiles for this group of bacteria.
High mortality associated with VRE suggests that glycopeptide intermediate-
and total-resistance isolates in Turkey will lead to serious medical problems in
clinical practice in the near future. With the expanded array of resistance pro-
files in enterococcal species, the use of glycopeptides is culture dependent.
Given the fact that the majority of these infections are due to E faecalis,8 the
combined use of ampicillin or penicillin with an aminoglycoside seems satisfac-
tory in probable infections with pending culture results.
Glycopeptide treatment has not been indicated in pneumococcal infections.
However, if a given community has >3% third-generation cephalosporin resis-
tance (MIC >0.05 µg/mL), the addition of vancomycin to treatment is indicated
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in probable pneumococcal CNS infections.61,103 As the present data did not report
a level >3%, the need for glycopeptide treatment of pneumococcal infections in
Turkey is not a reality. The addition of glycopeptides might be taken into consid-
eration under certain circumstances for life-threatening CNS infections: (1) the
antibacterial medication can be reassessed after obtaining the culture and sus-
ceptibility test results, including MICs; or (2) when diagnosis is based solely on
the indirect methods like Gram stain, the administration of vancomycin can be
considered if the treatment fails with third-generation cephalosporins.61
However, if the laboratory does not have the ability to test MIC of the infecting
pneumococcus, a clinical dilemma ensues, and the detection of oxacillin resis-
tance by disk diffusion test might lead to subsequent use of vancomycin.
CONCLUSIONS
In Turkey, a review of the existing literature found that the current use of glyco-
peptides in pneumococcal infections is restricted to CNS infections facing thera-
peutic failures in due course. However, the belief that these drugs are the last
resort, either in staphylococcal or enterococcal infections, is no longer valid and
their use in the treatment of pneumococcal infections is unecessary because of
existing resistance profiles. If a patient has a critical status probably due to these
gram-positive microorganisms, clinicians should consider the empiric use of gly-
copeptides. However, new molecules such as linezolid, QD and daptomycin, offered
for use in the treatment of gram-positive bacterial diseases, should be reserved
for the future when glycopeptides eventually become obsolete.
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